



Sorilux[®] (calcipotriene) – Expanded indication

- On November 5, 2019, the [FDA approved](#) Mayne Pharma's [Sorilux \(calcipotriene\)](#) foam, for the topical treatment of plaque psoriasis of the scalp and body in adults and pediatric patients 4 years of age and older.
 - Sorilux was previously approved for this indication in patients 12 years and older.
- The use of Sorilux in pediatric patients age 4 years and older is supported by two adequate and well controlled 8-week trials in adults and adolescents 12 years of age and older, with additional data from a 15-day open-label safety and pharmacokinetics (PK) study conducted in 19 subjects 12 to less than 17 years of age; and an 8-week open-label safety and PK study in 36 subjects 4 to 11 years of age with psoriasis.
- The recommended administration of Sorilux foam in all patients is an application of a thin layer twice daily to the affected areas.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.